stoxline Quote Chart Rank Option Currency Glossary
  
EQRx, Inc. (EQRX)
2.34  -0.05 (-2.09%)    11-08 16:00
Open: 2.39
High: 2.415
Volume: 11,934,302
  
Pre. Close: 2.39
Low: 2.32
Market Cap: 1,141(M)
Technical analysis
2023-11-17 4:49:51 PM
Short term     
Mid term     
Targets 6-month :  3.06 1-year :  3.58
Resists First :  2.62 Second :  3.06
Pivot price 2.23
Supports First :  2.24 Second :  2
MAs MA(5) :  2.38 MA(20) :  2.26
MA(100) :  2.15 MA(250) :  2.21
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  56.3 D(3) :  60.1
RSI RSI(14): 55.6
52-week High :  3.95 Low :  1.58
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ EQRX ] has closed below upper band by 30.7%. Bollinger Bands are 81.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.34 - 2.35 2.35 - 2.36
Low: 2.31 - 2.33 2.33 - 2.34
Close: 2.32 - 2.34 2.34 - 2.36
Company Description

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Headline News

Thu, 09 Nov 2023
EQRx's Acquisition by Revolution Medicines is Complete | News & Events | Goodwin - Goodwin Procter

Wed, 08 Nov 2023
Revolution Medicines and EQRx stockholders approve acquisition (NASDAQ:RVMD) - Seeking Alpha

Wed, 08 Nov 2023
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition - Yahoo Finance

Thu, 05 Oct 2023
The unraveling of EQRx's low-cost drug dream - Fierce Biotech

Wed, 02 Aug 2023
Revolution Medicines to buy biopharmaceutical firm EQRx - Pharmaceutical Technology

Tue, 01 Aug 2023
EQRx's Affordable Drugs Strategy Ends in Acquisition by Revolution, Interested Only in Its Cash - MedCity News

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 488 (M)
Shares Float 320 (M)
Held by Insiders 11.1 (%)
Held by Institutions 68.2 (%)
Shares Short 9,960 (K)
Shares Short P.Month 13,370 (K)
Stock Financials
EPS -0.55
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.41
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -13.8 %
Return on Equity (ttm) -20.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.63
Qtrly Earnings Growth 0 %
Operating Cash Flow -330 (M)
Levered Free Cash Flow -159 (M)
Stock Valuations
PE Ratio -4.34
PEG Ratio 0
Price to Book value 0.97
Price to Sales 0
Price to Cash Flow -3.46
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android